Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07706413

Plasma Exchange in Children With Severe Sepsis and Septic Shock

The aim of the study will be to to evaluate whether therapeutic plasma exchange (TPE) reduces mortality in critically ill children with severe sepsis or septic shock compared to the standard care of sepsis alone.

The study population will be divided into two groups, the first group will receive standard sepsis management plus therapeutic plasma exchange and the second one will receive the standard sepsis management alone . Then we will assess the effect of TPE on : Severity of organ dysfunction (pSOFA score) , duration of vasopressor support , length of PICU stay, time to hemodynamic stabilization , and on inflammatory and coagulation biomarkers

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

1 month–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Menoufia university hospital, Pediatric intensive care unit

Shibīn al Kawm, Menoufia Governorate, Egypt

Location contact

Amira Zaki Badawy, MD, clinical pathology

SUB_INVESTIGATOR

Hani Hamed Saad, MD, pediatrics

CONTACT

[email protected]

+201067610619

Hani Hamed Saad, MD, pediatrics

PRINCIPAL_INVESTIGATOR

Nagwan Yossery Saleh, MD, pediatrics

CONTACT

[email protected]

+201003961071

Nagwan Yossery Saleh, MD, pediatrics

SUB_INVESTIGATOR

About this study

This will be a Prospective, randomized, controlled, open- label, parallel-group, center clinical trial, which will be conducted on critically ill children with severe sepsis and septic shock, admitted into the Pediatric Intensive Care Unit (PICU) of Menoufia University Hospital from August 2026 to February 2027.

Eligible patients will be randomized using a computer-generated random sequence into:

  • - Intervention Group (plasma exchange Arm): Standard sepsis management plus therapeutic plasma exchange.
  • - Control Group (Standard care Arm): Standard sepsis management alone. Interventions

Standard Care (Both Groups):

  • - Early antimicrobial therapy
  • - Fluid resuscitation.
  • - Vasopressor and inotropic support
  • - Mechanical ventilation as indicated
  • - Organ support according to PICU protocols Therapeutic Plasma Exchange (TPE) Protocol
  • Initiation: Within 24 hours of diagnosis.
  • Frequency: Once daily for 1-5 sessions (Connelly et al.,2023)
  • Plasma Volume: 1-1.5 plasma volumes per session.
  • Replacement Fluid: Fresh frozen plasma (FFP).
  • Anticoagulation: Citrate or heparin according to institutional protocol.
  • Monitoring: Continuous hemodynamic and laboratory monitoring (All adverse events related to TPE (hypotension, bleeding, electrolyte disturbances, allergic reactions) will be recorded and managed according to PICU protocols.

All patients will be subjected to:

  • Demographic data will be collected from each participant, including age, sex, and weight, height, and body mass index.
  • Clinical Assessment:
  • Detailed history and physical examination.
  • Scoring of the severity of the disease using pSOFA (Pediatric Sequential Organ Failure Assessment) and PELOD-2 (Pediatric Logistic Organ Dysfunction 2) scores.
  • Laboratory investigations:
  • - Complete blood count (CBC). 2) - C-reactive protein (CRP). 3) - Procalcitonin (PCT). 4) - Coagulation profile (PT, aPTT and INR). 5) - Liver functions (ALT and AST). 6) - Kidney functions (Urea and creatinine). 7) - Electrolytes: Sodium (Na), potassium (K) and Calcium (Ca) levels. 8) - Serum lactate level and LDH. 9) - Blood cultures for all cases, urine and CSF culture (if indicated).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • From one month to 18 years.
  • With an established diagnosis of severe sepsis or septic shock according to international pediatric sepsis definitions.

Exclusion criteria

  • Known congenital bleeding disorders and severe uncontrolled hemorrhage.
  • End-stage chronic illness with expected survival < 3 months.
  • Previous plasma exchange during the same admission.
  • Contraindications to central venous catheterization.

Treatment and study plan

Plasma exchange (PE)

Procedure

Therapeutic plasma exchange to the intervention Group (plasma exchange Arm) that will receive also the standard sepsis management.

Primary outcomes

  1. Primary Outcome Measure

    Time frame: 28 days

    All-cause mortality within 28 days after randomization, defined as the proportion of participants who die from any cause within 28 days of enrollment.

Secondary outcomes

  1. Change in pediatric Sequential Organ Failure Assessment (pSOFA) score

    Time frame: Baseline, Day 1, Day 3, and Day 7

    Change in pSOFA score from baseline measured on days 1, 3, and 7 after randomization.

  2. Duration of vasopressor support

    Time frame: Up to 28 days

    Number of days participants require vasopressor support after randomization.

  3. Length of pediatric intensive care unit (PICU) stay

    Time frame: Up to 28 days

    Number of days participants remain admitted to the PICU.

  4. Time to shock resolution

    Time frame: Up to 28 days

    Time from randomization until resolution of septic shock

  5. Change in C-reactive protein (CRP)

    Time frame: Baseline, Day 3, and Day 7

    Change in serum CRP concentration from baseline.

  6. Change in procalcitonin concentration

    Time frame: Baseline, Day 3, and Day 7

    Change in serum procalcitonin concentration from baseline.

  7. Platelet count

    Time frame: Baseline, Day 3, and Day 7

    Change in platelet count from baseline.

  8. International normalized ratio (INR)

    Time frame: Baseline, Day 3, and Day 7

    Change in INR from baseline.

  9. Fibrinogen concentration

    Time frame: Baseline, Day 3, and Day 7

    Change in plasma fibrinogen concentration from baseline.

  10. Incidence of therapeutic plasma exchange-related adverse events

    Time frame: Up to 28 days

    Number of participants experiencing adverse events related to therapeutic plasma exchange.

Study contacts

Contact information is provided by the study sponsor or research team.

Hani Hamed Saad, MD, Pediatrics

CONTACT

[email protected]

+201067610619

Nagwan Yossery Saleh, MD, Pediatrics

CONTACT

[email protected]

+201003961071

Sponsors and collaborators

Lead sponsor

Menoufia University

Other

Registry information

Official study title

Therapeutic Plasma Exchange in Children With Severe Sepsis and Septic Shock: A Randomized Controlled Clinical Trial

Acronym: PE/Sepsis

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 15, 2026
Registry last updated
Jul 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.